Empagliflozin in patient with heart failure and type 2 diabetes mellitus: new possibilities for drug therapy-Reference-Cited by-同舟云学术

Empagliflozin in patient with heart failure and type 2 diabetes mellitus: new possibilities for drug therapy

Published:2021-10-19 Issue:29 Volume:1 Page:8-12
ISSN:2078-5631
Container-title:Medical alphabet
language:
Short-container-title:Medicinskij alfavit

Author:

Sedykh D. Yu.¹^ORCID,Kashtalap V. V.¹^ORCID,Barbarash O. L.¹^ORCID

Affiliation:

1. Research Institute for Complex Problems of Cardiovascular Diseases

Abstract

The article demonstrates the practical experience of the effective use of inhibitor of sodium-glucose co-transporter 2 emplagliflozin as a part of optimal drug therapy in patients with decompensation of chronic heart failure with systolic dysfunction of ischemic genesis and type 2 diabetes mellitus. The place of this group of drugs in improving the quality of life and prognosis in patients with severe comorbidity has been indicated according to the data of evidence-based studies.

Publisher

Alfmed LLC

Subject

Materials Chemistry,Economics and Econometrics,Media Technology,Forestry

Reference37 articles.

1. Barbarash O.L., Kashtalap V.V. The Place of Pharmacoinvasive Management in Patients With ST-Elevation Acute Coronary Syndrome in Russia. Kardiologiia. 2014; 9: 79–85 (in Russian).

2. Kashtalap V. V., Zavyrylina I. N., Barbarash O. L. Endovascular revascularization for ST-elevation acute coronary syndrome in Russia: problems and prospects for the further development. Kreativnaya kardiologiya. 2015; 3: 5–15 (in Russian).

3. Barbarash O.L., Kashtalap V.V., Bykova I.S., et al. Gender specifics of clinical course and in-patient stage of management in ST-elevation acute coronary syndrome patients (by the Russian Registry of Acute Coronary Syndrome RECORD-3. Russ J Cardiol. 2017; 6 (146): 122–131 (in Russian).

4. Koudstaal S., Pujades-Rodriguez M., Denaxas S., et al. Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people. Eur J Heart Fail. 2017; 19 (9): 1119–1127. DOI: 10.1002/ejhf.709.

5. Kobalava Zh.D., Lazarev P.V., Villevalde S.V. SGLT2 Inhibitors: Rationale and Perspectives of Use in Heart Failure. Kardiologiia. 2018; 58 (2): 42–54 (in Russian).